Effects of Metrizoate and Iohexol on the Liver at Visceral Angiography

Billström, Å.; Hietala, Sven‐Ola; Wirell, Staffan

doi:10.1177/028418518702800609

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, only small and transient changes of hepatic enzyme levels following hepatic angiography with iohexol were found in pigs (Jensen et al., 1980 ). Comparative clinical trials have been performed on various radiologic indications, where iohexol has been compared with conventional ionic contrast media show that there was no significant increase in serum values of hepatic or pancreatic enzymes nor of electrolytes following either of the two contrast media (Billström et al., 1987 ).…”

Section: Discussionmentioning

confidence: 99%

A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer is one of the most common cancers in the United States and treatment options are limited for patients who develop liver metastases. Several chemotherapeutic regimens have been used for transvascular liver-directed therapy in the treatment of colorectal liver metastases without clear evidence of superiority of one therapy over another. We describe the development of a novel nanoemulsion through combining irinotecan (IRI), a first line systemic agent used for the treatment of colon cancer, with lipiodol, an oily contrast medium derived from poppy seed oil, and evaluated its pharmacokinetic and biodistribution profile as a function of portal venous chemoembolization (PVCE) versus transarterial chemoembolization (TACE) delivery. The Tessari technique was used to create a stable emulsion (20 mg IRI mixed with 2 mL lipiodol) with resultant particle size ranging from 28.9 nm to 56.4 nm. Pharmacokinetic profile established through venous sampling in Buffalo rats demonstrate that the area under the curve (AUC 0À1 ) of IRI was significantly less after PVCE with IRI-lipiodol as compared to IRI alone (131 vs. 316 mg Ã min/mL, p-value ¼ .023), suggesting significantly higher amounts of IRI retention in the liver with the IRI-lipiodol nanoemulsion via first-pass extraction. Subseqent biodistribution studies in tumor-bearing WAG/Rjj rats revealed more IRI present in the tumor following TACE versus PVCE (29.19 ± 12.33 mg/g versus 3.42 ± 1.62; p-value ¼ .0033) or IV (29.19 ± 12.33 mg/g versus 1.05 ± 0.47; p-value ¼ .0035). The IRI-lipiodol nanoemulsion demonstrated an acceptable hepatotoxicity profile in all routes of administration. In conclusion, the IRI-lipiodol nanoemulsion via TACE showed promise and warrants further investigation as an option for the treatment of metastatic colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%